The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Sequence of administration of ibrutinib with obinutuzumab in R/R CLL patients
Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses results from a Phase Ib study of sequence of administration of ibrutinib, a BTK inhibitor, in combination with obinutuzumab, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
